Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — FY2019 Earnings Presentation

23 slides from Paratek Pharmaceuticals's earnings presentation, Feb 25, 2020

  1. Slide 1: Fourth Quarter & Full Year 2019 Financial Results & Corporate Update

    Fourth Quarter & Full Year 2019 Financial Results & Corporate Update February 25, 2020 Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK): A commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other pub

  2. Slide 2: Q4 and Full Year 2019 Earnings Call Agenda

    Q4 and Full Year 2019 Earnings Call Agenda Introduction Ben Strain, Vice President, Investor Relations & Corporate Communications Overview and Financial Highlights Evan Loh, M.D., Chief Executive Officer Fourth Quarter and Full Year 2019 Commercial Highlights Adam Woodrow, President & Chief Commerci

  3. Slide 3: Forward-looking statements disclaimer

    Third-party industry and market information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, has not been independently verified by, and should not be construed as a representation by, Paratek. The info

  4. Slide 4: Overview & Financial Highlights

    Overview & Financial Highlights Evan Loh, M.D. Chief Executive Officer Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK): A commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threa

  5. Slide 5: Financial Highlights Full Year & Fourth Quarter 2019

    Financial Highlights Full Year & Fourth Quarter 2019 Fourth Quarter 2019 Net Revenues = $9.0 million primarily driven by the launch of NUZYRA® NUZYRA net sales = $5.4 million (increase of ~74% versus 3Q 2019) Driven by increases in demand Other revenue = $3.6 million Driven by $3.0 million milestone

  6. Slide 6: BARDA BioShield Contract

    BARDA BioShield Contract A Unique Public-Private Partnership with Paratek

  7. Slide 7: NDA Submission of Omadacycline in China Accepted by NMPA

    New Drug Application (NDA) Submission of Omadacycline in China Accepted by the China National Medical Products Administration (NMPA) February 2020 Zai Lab announced that NMPA has accepted its NDA for omadacycline Seeking approval for the treatment of community-acquired bacterial pneumonia and acute

  8. Slide 8: SEYSARA: License Grant with Almirall for Greater China Region

    SEYSARA: Entered into a License Grant with Almirall for Greater China Region Greater China Region: Paratek will earn high single-digit royalties on net sales in the greater China region Almirall plans to develop sarecycline for acne in China, with a potential submission to the China National Medical

  9. Slide 9: Condensed Consolidated Statements of Operations

    Condensed Consolidated Statements of Operations (unaudited) (in thousands, except loss per share data)

  10. Slide 10: Paratek 2020 Financial Guidance

    Paratek 2020 Financial Guidance Revenue Guidance Note NUZYRA US Net Product Revenue ~$66M ~$38 million of these sales coming from the initial BARDA procurement of 2,500 anthrax treatment courses The initial NUZYRA BARDA procurement is anticipated to be secured in the first half of 2020 Royalty and C

  11. Slide 11: Strong Balance Sheet and Cash Runway

    Strong Balance Sheet and Cash Runway Guidance as of December 31, 2019 Key Metrics (unaudited) 12/31/19 balance Total Cash, Cash Equivalents, and Marketable Securities $215.4 million Long-term Debt Obligation3 $260.7 million Basic Shares Outstanding 39,827,749 Total Potentially Dilutive Securities1 1

  12. Slide 12: Fourth Quarter 2019 Commercial Highlights

    Fourth Quarter 2019 Commercial Highlights Adam Woodrow President & Chief Commercial Officer Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK): A commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or othe

  13. Slide 13: NUZYRA Attributes Provide A Modern-Day Solution

    NUZYRA Attributes Provide A Modern-Day Solution Addressing Bacterial Resistance and the Needs of Today’s Healthcare Systems NUZYRA is a once-daily oral and IV broad spectrum antibiotic Community Acquired Bacterial Pneumonia (CABP) Acute Bacterial Skin & Skin Structure Infections (ABSSSI) High and du

  14. Slide 14: NUZYRA U.S. Launch Underway

    NUZYRA U.S. Launch Underway Generated $11.5 million in Net Sales in 2019 Launched in the U.S. in February 2019 With particular strength seen with the oral formulation, NUZYRA is on track to have one of the most successful antibiotics launches in last decade NUZYRA generated $5.4 million in net sales

  15. Slide 15: Pipeline and Future Value Drivers

    Pipeline and Future Value Drivers Randy Brenner Chief Development & Regulatory Officer Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK): A commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other pub

  16. Slide 16: BARDA Project BioShield Contract Awarded To Paratek

    First-ever Bioshield award for an antibiotic for the Strategic National Stockpile Paratek was the sole recipient Valued at up to $285 million over 5 years, with potential for extension up to 10 years $77 million in reimbursement for all existing post-approval obligations $54 million for anthrax deve

  17. Slide 17: Paratek / BARDA Milestones

    Paratek / BARDA Milestones Events Timing Value Comments BASE AWARD Treatment of Anthrax Development Program Deb 2019 ~$20M Anthrax Development Initiated Execute Purchase of Initial 2,500 Treatment Courses for BARDA Project BioShield Q2 2020 ~$38M Product Placed on VMI for SNS IMPORTANT MILESTONES Fi

  18. Slide 18: Paratek Pipeline

    Paratek Pipeline Research Preclinical Phase 1 Phase 2 Phase 3 Registration Marketed in the U.S. Commercial Rights SEYSARA® (sarecycline) (U.S.+) (ex-U.S.) ABSSSI (IV & Oral) – QIDP CABP (IV & Oral) – QIDP Inflammatory Acne (Acne Vulgaris) *We have entered into a collaboration agreement with Zai Lab

  19. Slide 19: NTM (M. abscessus) Rare Disease Opportunity

    NTM (M. abscessus) Rare Disease Opportunity Potential $740 Million Addressable Market by 2028 NTM (M. abscessus) Opportunity with Once Daily Oral Therapy = X = >75%(2) Fail triple generic Tx ~4,760 patients $155,420(3) per course $740M opportunity (1) Assumes 2028 NTM incidence of 72k, of which 9% i

  20. Slide 20: Potential Opportunity with Omadacycline in NTM

    Nontuberculous mycobacteria or “NTM” Potential Opportunity with Omadacycline Prevalence of All NTM 70,000 – 80,000 NTM cases in the U.S. 5-10% year-over-year increase in prevalence 5 year all-cause mortality 40% Paratek focused on subset of NTM patients (~6,000-8,000) with Mycobacterium abscessus Cu

  21. Slide 21: Q&A

    Q&A Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK): A commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use

  22. Slide 22: Closing Remarks

    Closing Remarks Evan Loh, M.D. Chief Executive Officer Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK): A commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian,

  23. Slide 23: Paratek is Well-Positioned for Future Growth

    Paratek is Well-Positioned for Future Growth Focused on Execution + New Value Creation Near-term Execution Future Value Creation Advance NUZYRA® U.S. Launch Disciplined Operating Expense Management Capitalize on Project BioShield Opportunity NUZYRA in Nontuberculous Mycobacteria or “NTM” Oral-only d

Paratek Pharmaceuticals — FY2019 Earnings Presentation on 6ix